Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 561-573

  Kaur, Harpreet ^a   Burden Gulley, Susan M ^a   Phillips Mason, Polly J ^a   Basilion, James P ^b   Sloan, Andrew E ^a   Brady Kalnay, Susann M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Biomedical Engineering   (United States)

Author keywords

Cell growth; Cell survival; Glioma; PTPmu (PTP); Receptor protein tyrosine phosphatase

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE MU; PROTEIN TYROSINE PHOSPHATASE MU E SUBUNIT; PROTEIN TYROSINE PHOSPHATASE MU P SUBUNIT; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; LENTIVIRUS; MICE; MICE, NUDE; PROTEOLYSIS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; RNA, SMALL INTERFERING;

EID: 84860372885     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos066     Document Type: Article

References (48)

1. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
3. Louis DN, Ohgaki H, WiestlerOD, CaveneeWK, eds.WHOClassification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC; 2007.
4. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci. 2007;64(4): 458-478.
5. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010;9:135.
6. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21): 2683-2710.
7. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638-655.
8. Lamszus K, Gunther HS. Glioma stem cells as a target for treatment. Target Oncol. 2010;5(3):211-215.
9. Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery. 2008;62(2):505-514; discussion 514-505.
10. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23(43):7267-7273.
11. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440-452.
12. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
13. Gladson CL, Prayson RA, Liu WM. The pathobiology of glioma tumors. Annu Rev Pathol. 2010;5:33-50.
14. Kanu OO, Hughes B, Di C, et al. Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol. 2009;3:39-52.
15. Fan QW, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007;67(17):7960-7965.
16. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005;4(1):101-112.
17. Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia. 2005;7(10):921-929.
18. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006;67(1):156-158.
19. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12(3, pt 1):860-868.
20. Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009;92(1):99-105.
21. Hjelmeland AB, Lattimore KP, Fee BE, et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther. 2007;6(9):2449-2457.
22. Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol. 2010;119(2):157-175.
23. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 1997;9(2):193-204.
24. Ö stman A, Hellberg C, Bö hmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6(4):307-320.
25. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833-846.
26. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011;11(1):35-49.
27. Gebbink MF, Zondag GC, Wubbolts RW, Beijersbergen RL, van Etten I, Moolenaar WH. Cell-cell adhesion mediated by a receptor-like protein tyrosine phosphatase. J Biol Chem. 1993;268(22):16101-16104.
28. Brady-Kalnay SM, Flint AJ, Tonks NK. Homophilic binding of PTP mu, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation. J Cell Biol. 1993;122(4):961-972.
29. Brady-Kalnay SM, Tonks NK. Identification of the homophilic binding site of the receptor protein tyrosine phosphatase PTP mu. J Biol Chem. 1994;269(45):28472-28477.
30. Burgoyne AM, Palomo JM, Phillips-Mason PJ, et al. PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol. 2009;11(6):767-778.
31. Craig SE, Brady-Kalnay SM. Cancer cells cut homophilic cell adhesion molecules and run. Cancer Res. 2011;71(2):303-309.
32. Burgoyne AM, Phillips-Mason PJ, Burden-Gulley SM, et al. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res. 2009;69(17):6960-6968.
33. Burden-Gulley SM, Gates TJ, Burgoyne AM, et al. A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. Neoplasia. 2010;12(4):305-316.
34. Hjelmeland AB, Wu Q, Heddleston JM, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011;18(5):829-840.
35. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007;26(24):4985-4995.
36. Brady-Kalnay SM, Tonks NK. Purification and characterization of the human protein tyrosine phosphatase, PTP mu, from a baculovirus expression system. Mol Cell Biochem. 1993;127-128:131-141.
37. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International. 2004;11(7):36-42.
38. Campan M, Yoshizumi M, Seidah NG, Lee ME, Bianchi C, Haber E. Increased proteolytic processing of protein tyrosine phosphatase mu in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Biochemistry. 1996;35(12):3797-3802.
39. Gebbink MF, Zondag GC, Koningstein GM, Feiken E, Wubbolts RW, Moolenaar WH. Cell surface expression of receptor protein tyrosine phosphatase RPTP mu is regulated by cell-cell contact. J Cell Biol. 1995;131(1):251-260.
40. Anders L, Mertins P, Lammich S, et al. Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity. Mol Cell Biol. 2006;26(10):3917-3934.
41. Rosenblum ML, Knebel KD, Wheeler KT, Barker M, Wilson CB. Development of an in vitro colony formation assay for the evaluation of in vivo chemotherapy of a rat brain tumor. In Vitro Cellular & Developmental Biology. 1975;11(5):264-273.
42. Kapoor GS, O'Rourke DM. Signaling modules in glial tumors and implications for molecular therapy. In: Janigro, D, ed. The Cell Cycle in the Central Nervous System. Totowa, NJ: Humana Press; 2006.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
44. Mayor R, Carmona-Fontaine C. Keeping in touch with contact inhibition of locomotion. Trends Cell Biol. 2010;20(6):319-328.
45. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011;21(4):228-237.
46. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009; 11(2):162-171.
47. Ruhe JE, Streit S, Hart S, Ullrich A. EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal. 2006;18(9):1515-1527.
48. Haapasalo A, KimDY,CareyBW, Turunen MK,PettingellWH, KovacsDM. Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin. J Biol Chem. 2007;282(12): 9063-9072.